Artiva Biotherapeutics (ARTV) Depreciation & Amortization (CF) (2023 - 2026)
Artiva Biotherapeutics (ARTV) posted quarterly Depreciation & Amortization (CF) of $666000.0 for Q1 2026, up 6.05% year-over-year from $628000.0 in Q1 2025, and little changed quarter-over-quarter from $666000.0 in Q4 2025.
Powered by 
Analysis
Artiva Biotherapeutics (ARTV) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported Depreciation & Amortization (CF) for 4 consecutive years, with $666000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 6.05% year-over-year to $666000.0; the TTM figure through Mar 2026 stood at $2.6 million (up 6.59% YoY), while the FY2025 annual figure was $2.6 million, up 6.83% from the prior year.
- Depreciation & Amortization (CF) steadied at $666000.0 in Q1 2026 per ARTV's latest filing, from $666000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $666000.0 in Q4 2025 and bottomed at $500000.0 in Q2 2023.
- Historically, Depreciation & Amortization (CF) has averaged $612000.0 across 4 years, with a median of $620500.0 in 2024.
- On a YoY basis, Depreciation & Amortization (CF) climbed as much as 20.6% in 2024 and fell as far as 3.37% in 2024.
- Artiva Biotherapeutics' Depreciation & Amortization (CF) stood at $594000.0 in 2023, then gained by 3.37% to $614000.0 in 2024, then grew by 8.47% to $666000.0 in 2025, then changed by 0.0% to $666000.0 in 2026.
- Business Quant data shows ARTV's Depreciation & Amortization (CF) at $666000.0 in Q1 2026, $666000.0 in Q4 2025, and $662000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Artiva Biotherapeutics | 441.23 Mn | 441.23 Mn | - | 692,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 692,000.00 |
| Mar 31, 2026 | 666,000.00 |
| Dec 31, 2025 | 666,000.00 |
| Sep 30, 2025 | 662,000.00 |
| Jun 30, 2025 | 641,000.00 |
| Mar 31, 2025 | 628,000.00 |
| Dec 31, 2024 | 614,000.00 |
| Sep 30, 2024 | 627,000.00 |
| Jun 30, 2024 | 603,000.00 |
| Mar 31, 2024 | 587,000.00 |
| Dec 31, 2023 | 594,000.00 |
| Sep 30, 2023 | 556,000.00 |